16,402 Shares in Guardant Health, Inc. $GH Acquired by Quantbot Technologies LP

Quantbot Technologies LP acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 16,402 shares of the company’s stock, valued at approximately $2,461,000.

Other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC bought a new position in shares of Guardant Health in the fourth quarter worth $35,000. Parallel Advisors LLC lifted its position in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the period. Ascentis Independent Advisors bought a new stake in Guardant Health during the first quarter worth about $38,000. Hollencrest Capital Management acquired a new stake in Guardant Health during the first quarter worth about $41,000. Finally, EFG International AG acquired a new stake in Guardant Health during the fourth quarter worth about $41,000. 92.60% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Guggenheim lifted their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. BTIG Research upped their target price on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Mizuho raised their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Insider Activity at Guardant Health

In related news, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the sale, the insider owned 65,374 shares of the company’s stock, valued at $11,086,122.92. This trade represents a 49.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ian T. Clark sold 14,180 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total value of $2,253,485.60. Following the sale, the director owned 2,975 shares in the company, valued at $472,787. This represents a 82.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 521,818 shares of company stock worth $77,539,233 over the last 90 days. 5.60% of the stock is currently owned by company insiders.

Guardant Health Price Performance

GH stock opened at $170.69 on Monday. The stock has a market cap of $22.91 billion, a price-to-earnings ratio of -48.91 and a beta of 1.60. The company has a 50 day simple moving average of $153.91 and a 200 day simple moving average of $118.72. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. The business’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.44) EPS. On average, equities research analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.